Should You Buy Bioventus Inc (BVS) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Hold
Latest Price
7.820
1 Day change
0.77%
52 Week Range
11.250
Analysis Updated At
2026/01/28
BVS is not a good buy right now for a beginner long-term investor with $50k–$100k who doesn’t want to wait for a better entry. The chart is mildly bullish, but fundamentals are weakening (net income/EPS down sharply in 2025/Q3) and options are pricing extreme uncertainty (IV percentile ~99). Without near-term catalysts or strong proprietary signals, the risk/reward is not attractive for an “impatient” long-term entry today.
Technical Analysis
Trend/price action: Mild bullish bias. Moving averages are stacked bullish (SMA_5 > SMA_20 > SMA_200), suggesting an uptrend/positive structure. Momentum: MACD histogram is slightly above zero (0.00204) but positively contracting, implying upside momentum is present but fading. RSI(6) at ~55 is neutral—no strong overbought/oversold edge.
Key levels: Current price 7.79 is below the pivot (7.949). Near-term support: S1 7.653 then S2 7.47. Resistance: pivot 7.949, then R1 8.245 and R2 8.428. For an impatient entry, buying below the pivot with fading MACD momentum is not ideal because the stock still needs to reclaim ~7.95 convincingly to improve odds of a quick move higher.
Intellectia Proprietary Trading Signals:
**Intellectia Proprietary Trading Signals**
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock recently.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Sentiment: Extremely call-heavy open interest (put/call OI ratio 0.08; calls OI 1395 vs puts OI 105), which is typically bullish positioning.
Caveats: Today’s option volume is very low (total volume 10; calls volume 0, puts volume 10), so the put/call volume ratio of 0.0 is not a strong real-time sentiment read—liquidity is thin.
Volatility/pricing: Implied vol (30D) ~158% vs historical vol ~55% with IV percentile 99.2 (very elevated). This suggests the market is pricing unusually large moves/uncertainty; for a beginner long-term buyer, that’s a poor setup to initiate without a clear catalyst.
Technical Summary
Sell
3
Buy
9
Positive Catalysts
Technical structure is currently bullish via moving averages (SMA_5 > SMA_20 > SMA_200).
Options open interest is heavily skewed to calls (bullish positioning).
Gross margin improved in 2025/Q3 (66.95%, +1.70% YoY), showing some operational improvement on profitability at the gross level.
Institutional/insider flow: Hedge funds and insiders are neutral (no notable selling pressure flagged).
Neutral/Negative Catalysts
with MACD momentum contracting—near-term upside follow-through is not strong.
Financial Performance
Latest quarter: 2025/Q3. Revenue was 138.651M, down -0.23% YoY (flat-to-slightly down growth). Net income fell to 3.155M, down -161.08% YoY, and EPS fell to 0.05, down -162.50% YoY—clear earnings weakness. Gross margin improved to 66.95% (+1.70% YoY), which is a positive efficiency signal, but it did not translate into bottom-line growth in this quarter.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating trend or price target change data was provided, so a Wall Street pros/cons consensus assessment cannot be reliably summarized from the given dataset. (Other influence/flow checks: no recent congress trading data available; hedge funds and insiders are neutral with no significant recent trend.)
Wall Street analysts forecast BVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BVS is 15 USD with a low forecast of 15 USD and a high forecast of 15 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast BVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BVS is 15 USD with a low forecast of 15 USD and a high forecast of 15 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 7.760
Low
15
Averages
15
High
15
Current: 7.760
Low
15
Averages
15
High
15
Cantor Fitzgerald
Ross Osborn
Overweight
initiated
$12
AI Analysis
2025-07-07
Reason
Cantor Fitzgerald
Ross Osborn
Price Target
$12
AI Analysis
2025-07-07
initiated
Overweight
Reason
Cantor Fitzgerald analyst Ross Osborn initiated coverage of Bioventus with an Overweight rating and $12 price target.
